HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.

Abstract
The deficiency of methylthioadenosine phosphorylase (MTAP) in T-cell acute lymphoblastic leukemia (T-ALL) and other cancers, while constitutively expressed in normal cells, allows for selective therapy using L-alanosine, an inhibitor of de novo AMP synthesis. We demonstrate that MTAP- T-ALL cells obtained at relapse are as sensitive to L-alanosine toxicity as diagnosis samples. The therapeutic index of L-alanosine can be increased by the use of a MTAP substrate, which protects MTAP+ normal cells. Since MTAP substrates MTA and 5'deoxyadenosine are prone to toxicities associated with adenosine, we synthesized and evaluated a potentially nontoxic MTAP substrate, 9-beta-D-erythrofuranosyladenine (EFA). The cytotoxicity of EFA to hematopoietic progenitors erythroid burst-forming units (BFU-Es) and granulocyte-macrophage colony-forming units (CFU-GMs) was at least 26- to 41-fold less than that of MTA. In addition, EFA selectively rescued MTAP+ MOLT-4 cells from L-alanosine toxicity at 25 microM with negligible toxicity even at 100 microM. As for MTA, significant, albeit incomplete, rescue was achieved at 12.5 microM, but higher concentrations were toxic. EFA at 20 microM or less rescued primary MTAP+ T-ALL cells and normal lymphocytes from L-alanosine toxicity. Collectively, these data indicate that EFA is an effective agent for salvaging MTAP+ cells from L-alanosine toxicity and is superior to MTA due to lower cytotoxicity.
AuthorsAyse Batova, Howard Cottam, John Yu, Mitchell B Diccianni, Carlos J Carrera, Alice L Yu
JournalBlood (Blood) Vol. 107 Issue 3 Pg. 898-903 (Feb 01 2006) ISSN: 0006-4971 [Print] United States
PMID16234352 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • 9-beta-D-erythrofuranosyladenine
  • Antibiotics, Antineoplastic
  • Deoxyadenosines
  • Enzyme Inhibitors
  • Furans
  • Thionucleosides
  • alanosine
  • 5'-methylthioadenosine
  • Purine-Nucleoside Phosphorylase
  • 5'-methylthioadenosine phosphorylase
  • Adenine
  • Alanine
Topics
  • Adenine (analogs & derivatives, pharmacology, therapeutic use)
  • Alanine (adverse effects, analogs & derivatives, pharmacology, therapeutic use)
  • Antibiotics, Antineoplastic (adverse effects, pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Deoxyadenosines (pharmacology, therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical
  • Enzyme Inhibitors (adverse effects, pharmacology, therapeutic use)
  • Erythroid Precursor Cells (enzymology, pathology)
  • Furans (pharmacology, therapeutic use)
  • Granulocyte Precursor Cells (enzymology, pathology)
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell (drug therapy, enzymology, pathology)
  • Purine-Nucleoside Phosphorylase (antagonists & inhibitors, deficiency)
  • Salvage Therapy
  • Thionucleosides (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: